From Plant to Patient: What Scientists Were Learning About Cannabis Medicine in 2001
A conference report documented that whole cannabis extracts appeared more effective than single cannabinoids for muscle spasticity, and that multiple clinical trials were underway for pain and multiple sclerosis.
Quick Facts
What This Study Found
The conference highlighted several emerging findings in cannabinoid medicine. Whole cannabis plant constituents, including cannabinoids and possibly flavonoids, appeared more effective than a single isolated cannabinoid in reducing muscle spasticity in an animal model of multiple sclerosis. This suggested that interactions between multiple compounds in the plant contributed to therapeutic effects.
Synthetic cannabinoids with high receptor affinity were available, and pharmaceutical products targeting the endocannabinoid system through uptake and metabolism blockade were being developed. Government and charity-funded clinical trials were proceeding in acute pain, chronic pain, and multiple sclerosis across the UK.
Key Numbers
No specific quantitative data were reported in this conference summary.
How They Did This
This was a conference proceedings report summarizing presentations at a scientific meeting on cannabinoids held in London in April 2001. It compiled findings from multiple presenters rather than reporting original research.
Why This Research Matters
This report captured the state of cannabinoid medicine at a pivotal moment when the field was transitioning from preclinical research to large-scale clinical trials. The observation that whole-plant extracts outperformed single cannabinoids would become an important concept in cannabis pharmacology, later termed the "entourage effect."
The Bigger Picture
The UK Medical Research Council trials referenced in this report would help build the evidence base that eventually led to the approval of Sativex (nabiximols) for multiple sclerosis spasticity. The concept of whole-plant superiority over isolated compounds continues to drive research into full-spectrum cannabis products.
What This Study Doesn't Tell Us
Conference proceedings provide a snapshot of presented findings without the rigor of peer-reviewed original research. The animal model findings on whole-plant superiority may not directly translate to human outcomes. Specific data and effect sizes from the presentations were not included.
Questions This Raises
- ?Which specific plant constituents beyond THC and CBD contributed to the enhanced effect in spasticity models?
- ?How did the results of the MRC multicenter trials ultimately compare to single-cannabinoid treatments?
Trust & Context
- Key Stat:
- Whole-plant extracts outperformed single cannabinoids in MS spasticity model
- Evidence Grade:
- This is a conference proceedings summary without original data or systematic methodology, providing preliminary-level evidence.
- Study Age:
- Published in 2001, this captures early-stage research that would lead to approved cannabinoid medications in subsequent years.
- Original Title:
- Cannabinoids - from plant to patient. 5 April 2001, London, UK.
- Published In:
- IDrugs : the investigational drugs journal, 4(7), 773-5 (2001)
- Authors:
- Holdcroft, A
- Database ID:
- RTHC-00107
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the entourage effect?
The entourage effect refers to the theory that multiple compounds in cannabis work together to produce effects greater than any single compound alone. This conference report described early evidence supporting this concept.
Did the clinical trials mentioned in this report lead to approved medications?
Yes. Research on whole-plant cannabis extracts for multiple sclerosis eventually led to the development and approval of Sativex (nabiximols), a mouth spray containing THC and CBD.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- entourage-effect-whole-plant-cannabis
- full-spectrum-vs-broad-spectrum-vs-isolate
Cite This Study
https://rethinkthc.com/research/RTHC-00107APA
Holdcroft, A. (2001). Cannabinoids - from plant to patient. 5 April 2001, London, UK.. IDrugs : the investigational drugs journal, 4(7), 773-5.
MLA
Holdcroft, A. "Cannabinoids - from plant to patient. 5 April 2001, London, UK.." IDrugs : the investigational drugs journal, 2001.
RethinkTHC
RethinkTHC Research Database. "Cannabinoids - from plant to patient. 5 April 2001, London, ..." RTHC-00107. Retrieved from https://rethinkthc.com/research/holdcroft-2001-cannabinoids-from-plant-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.